These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15533657)

  • 41. Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study.
    Trompetto C; Avanzino L; Bove M; Buccolieri A; Uccelli A; Abbruzzese G
    Clin Neurophysiol; 2008 Jan; 119(1):63-70. PubMed ID: 18042426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A case of tardive dystonia].
    Jyoichi T; Ebisawa T; Noda Y; Matsui K; Miyahara T
    Rinsho Shinkeigaku; 1989 Jan; 29(1):59-62. PubMed ID: 2568208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis.
    Di Pauli F; Reindl M; Ehling R; Schautzer F; Gneiss C; Lutterotti A; O'Reilly E; Munger K; Deisenhammer F; Ascherio A; Berger T
    Mult Scler; 2008 Sep; 14(8):1026-30. PubMed ID: 18632775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Secondary progressive multiple sclerosis in childhood--interferon beta 1b treatment].
    Higurashi N; Hamano S; Eto Y
    No To Hattatsu; 2006 May; 38(3):209-13. PubMed ID: 16715936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of iron dysregulation in the pathogenesis of multiple sclerosis: an Egyptian study.
    Abo-Krysha N; Rashed L
    Mult Scler; 2008 Jun; 14(5):602-8. PubMed ID: 18408021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A pathomechanism for the genesis of dystonia: striatal compartments and hypothesized model of basal ganglia circuits].
    Goto S
    Rinsho Shinkeigaku; 2006 Nov; 46(11):963-6. PubMed ID: 17432234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hereditary progressive dystonia with marked diurnal fluctuation. Pathophysiological importance of the age of onset.
    Segawa M; Nomura Y
    Adv Neurol; 1993; 60():568-76. PubMed ID: 8420193
    [No Abstract]   [Full Text] [Related]  

  • 51. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Acute encephalitis: bilateral lesions of the basal ganglia].
    Grippo J; Grippo T
    Rev Neurol; 2001 Sep 16-30; 33(6):537-40. PubMed ID: 11727235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ADC measurements in various patterns of multiple sclerosis lesions.
    Phuttharak W; Galassi W; Laopaiboon V; Laopaiboon M; Hesselink JR
    J Med Assoc Thai; 2006 Feb; 89(2):196-204. PubMed ID: 16579006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natalizumab treatment in pediatric multiple sclerosis: a case report.
    Borriello G; Prosperini L; Luchetti A; Pozzilli C
    Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical features of corticobasal degeneration].
    Farsang M; Takáts A; Szirmai I; Kovács T
    Ideggyogy Sz; 2005 Jan; 58(1-2):45-51. PubMed ID: 15884398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients.
    Watanabe A; Matsushita T; Doi H; Matsuoka T; Shigeto H; Isobe N; Kawano Y; Tobimatsu S; Kira J
    J Neurol Sci; 2009 Jun; 281(1-2):34-40. PubMed ID: 19339021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families.
    Nardocci N; Zorzi G; Barzaghi C; Zibordi F; Ciano C; Ghezzi D; Garavaglia B
    Mov Disord; 2008 Jan; 23(1):28-34. PubMed ID: 17853490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.